

Title of the article: Effect of various hormonal and non-hormonal contraceptive methods on the vaginal milieu -A narrative review

Running -Contraception and vaginal milieu

Number of tables-4

Number of figures-0

Source of financial support-Nil

Authors full names, highest academic degrees, affiliations, and postal address

1.Dr Deepti Tandon (First and corresponding author)

MBBS,M.S Obstetric & Gynaecology

Scientist B

Department of Clinical Research

ICMR- National Institute for Research in Reproductive and Child Health (NIRRCH)

J.M. Street, Parel, Mumbai 400012

Phone no-02224192030,9971719864

Email ID-gdeepti167@gmail.com

2. Dr Anushree D Patil

M.D Obstetric & Gynaecology

Scientist E

Department of Clinical Research

ICMR- National Institute for Research in Reproductive and Child Health (NIRRCH)

J.M. Street, Parel, Mumbai 400012

Email ID: rajshrinm@yahoo.co.in

Phone no-02224192028

3.Miss Mayuri Goriwale

MSc

Project Technician
Department of Clinical Research
ICMR- National Institute for Research in Reproductive and Child Health (NIRRCH)
J.M. Street, Parel, Mumbai 400012

Acknowledgements The authors acknowledge the encouragement and guidance received from Director, ICMR-NIRRH and Dr Sanjay Chauhan Head of Operational & Clinical research ICMR NIRRH .

Conflict of interest-There is no conflict of interest

Effect of various hormonal and non-hormonal contraceptive methods on the vaginal milieu -A narrative review

Abstract:

Globally the use of modern contraceptive methods has risen to 851 million. Use of these contraceptive methods does influence the vaginal health, which in turn affects the susceptibility towards acquiring RTI/STI. Methods to assess the vaginal health have also evolved over decades. The objective of this narrative review is to assess the influence of contraceptive methods on the vaginal health and also evaluate the methods used to assess the vaginal milieu. Suitable articles published in literature from 2007-2020 were identified from PubMed, Google Scholar using relevant keywords. Hormonal contraceptives included were combined oral contraceptive pills (COCP), Depot medroxyprogesterone acetate (DMPA) and Levonorgestrel IUCD (LNG-IUS). Non hormonal methods included were barrier methods, copper IUCD, diaphragm and vaginal sponge. Outcome parameter recorded were Nugent score, vaginal pH, bacterial vaginosis or defined microbiome profile.

COCP have been shown to protect the vaginal ecosystem primarily due to their oestrogen component. The use of IUCD causes initial dysbiosis chiefly due to associated irregular bleeding but long term use of LNG IUS stabilizes the microbiome. Use of injectable DMPA though does not increase the susceptibility to HIV but can promote growth of anaerobic organisms. Literature regarding condom, diaphragm and sponge is very scanty to draw a meaningful conclusion. Hence contraceptive methods can affect the vaginal health. There is need to periodically assess the vaginal milieu using test which is appropriate as per available expertise, infrastructure and cost and treat vaginal dysbiosis in respective cohorts to prevent reproductive morbidity.

Keywords-Contraception OR Nugent score, Contraception OR Vaginal microbiome, Contraception OR Bacterial vaginosis, Contraception OR Vaginal pH

1. Introduction:

Worldwide as per world family planning highlights 2020, the number of women using modern or traditional methods of contraception are 851 and 85 million respectively.¹ The vaginal ecosystem is dynamic, vulnerable and susceptible to change in response to exposure to various external stimuli such as hormones and allergens.² Any positive or negative changes in these vaginal health is termed as vaginal eubiosis or vaginal dysbiosis respectively. This vaginal eubiosis is protective but the dysbiosis makes the women prone to various degrees of common but significant reproductive morbidities such as bacterial vaginosis, recurrent vaginal infections, risk of acquiring sexually transmitted infections, urinary tract infection, HIV transmission, pelvic inflammation and preterm births.^{3,4} There have been conflicting evidence in literature regarding the effect of available contraception methods on the vaginal health of women. The impact of these hormonal and non-hormonal contraceptives is dependent on the host factors which are further affected by the local immune responses, vaginal bacterial communities, competition and release of bactericidal products, or any inflammation acquired due to prolonged use.⁵

This narrative review will help us understand the effect of various hormonal and non-hormonal contraceptive methods on vaginal health and further evaluate the various methods used to assess vaginal milieu

2. Methodology:

In this narrative review the search engines that were explored were Pubmed and Google Scholar. The following keywords were used for the research: Contraception and Vaginal microbiome OR Contraception and Nugent score OR Contraception and Bacterial vaginosis

OR Contraception and vaginal pH. The studies which met the following criteria were included in the current review

1. Prospective studies published in English
2. Published in last fourteen years 2007-2020 irrespective of data collection period
3. Studies mentioning the contraceptive method used

3. Results:

The studies and their findings are described in brief. Data is compiled and interpreted to give a comprehensive overview of effect of various contraception method on the vaginal milieu.

Individual contraceptives are discussed under the following subheading-

3.1. IUCD and vaginal milieu:

Copper containing devices such as copper T 380 A and copper T 375 are more commonly used and provide contraceptive benefits up to ten years and five years respectively. Hormonal IUCD contain levonorgestrel in variable quantities and have effectiveness between 3-5 years. Commonly used hormonal IUCD are Mirena, Skyla, Liletta and Kyleena.

As reported in literature various studies have been done to evaluate the effect of copper T as well as LNG IUCD on the vaginal health of women.^{6,7,8,9,10,11,12,13,14,15,16} These studies have been enumerated in Table 1.

As inference from Table 1, literature does suggest an association between use of copper IUCD and dysbiotic vaginal health leading to increased vaginal discharge, bacterial vaginosis, increase in inflammatory cytokines and increased colonization by candida.^{7,8,11,12,13,14,15} Further evaluation of the effect of levonorgestrel intrauterine system (LNG-IUS) on lower genital tract is conflicting. Literature does suggest that there is increase in prevalence of dysbiotic microbiome profile and raised cytokine profile after use of LNG IUCD.^{8,9} There has been an observation of increased colonization of candida species after long term use as suggested by Donders et al and Lessard T et al. Reactional changes in the

vaginal environment have also been observed in a recent study by Giraldo et al.^{6,11,16} Few studies have reported a positive influence on the community stability with use of LNG IUCD but studies by Bassis et al and Jacobson et al found no evidence that LNG contraception altered the vaginal microbiota composition.^{10,12,17}

3.2. Oral contraceptives and vaginal milieu:

Oral contraceptives are hormonal contraceptives containing oestrogen and progesterone or only progesterone. The most commonly used is the one containing both oestrogen and progesterone.

Fosch et al in 2017 used the Balance of Vaginal Content (BAVACO) methodology to assess the vaginal health after use of this contraceptive. This methodology used two parameters- Nugent scoring and vaginal inflammatory reaction to give a composite score of vaginal health.¹⁸ Continuous and sustained use of oral contraceptive pills over a period of six months led to the stability of vaginal ecosystem. *Lactobacillus crispatus* followed by *Lactobacillus jensenii* has been found to be a predominant organism by Brooks et al and Fosch et al after use of combined oral contraceptive pills which in turn was protective species and promoter of vaginal health.^{9,18} Studies as summarized in table 2 shows the various studies in literature which have evaluated the use of oral contraceptive pills and on vaginal health.^{18,19,20,21} Majority of the studies show a relatively stable vaginal ecosystem after the use of oral contraceptive pills. Brotman et al and Rifkin et al showed stable bacterial communities in various cohorts respectively.^{19,20} Increased oestrogen though promoted the vaginal colonization by yeast cells in oral contraceptive users.¹⁸

3.3. DMPA and vaginal milieu:

Depo-Provera or Depot medroxyprogesterone acetate is progesterone containing injectable contraceptive, which is administered every after three months.

Meta-analysis done by Ralph et al echoed that there was moderate increase in HIV acquisition especially in high-risk population after DMPA use.²² Yang et al in 2019 pointed out that the microbiome becomes diversified and shows higher colonization of *Prevotella* OTUs after continuous use of DMPA, though it's the racial diversity in the vaginal microbiome which determines their susceptibility towards acquiring STI.²³

Retrospective study by Brooks et al in 2017 suggest that use of DMPA is associated with increase in colonization by *A. vaginae* and *P. Biviano* , hence a detrimental effect was seen on the vaginal microbiota.⁹ Animal studies on pigtail macaques by Butler K also validated that risk of HIV acquisition is increased in a dose dependent manner.²⁴ Though there was mounting evidence that the risk of STI especially HIV transmission is increased with use of DMPA, the result of ECHO Study (Evidence for Contraceptive Options in HIV Outcomes) published on June 13, 2019 shows that there was no risk of acquiring HIV infection. This largest multicentre, open label, randomized trial done between 2015 to 2017 across four centres on 2609 women using DMPA suggest no substantial risk of HIV.²⁵ Hence summarization of all these studies as tabulated in Table 3 suggest that the vaginal microbiota is probably altered with increase in the species especially *Prevotella* OTUs and *A. vaginae* .
26,27,28

3.4. Condom and Vaginal Milieu:

Condoms are one of the non-hormonal reversible, cost effective and easy to use contraception method used by many men during the intercourse. Use of condoms has prevented the transmission of Sexually Transmitted Infections (STIs) worldwide.

Fosch et al. in 2017 studied the vaginal ecosystem of eight women after continuous use of condom. As per the study, there was an increase in the vaginal inflammatory reaction due to latex allergy. *L. Gasseri* was the most commonly found followed by *L. crispatus*, *L. jensenii*, *L. murinus* and *L. Johnsonii* in the order.¹⁸

Liyan Ma et al. in 2013 studied effect of use of condom on the vaginal milieu. The study concluded that consistent effect of condoms increases the colonization of *Lactobacillus crispatus* which indeed was protective for bacterial vaginosis and HIV.²⁹ Table 4 elaborates the studies of vaginal milieu after condom use.

3.5. Miscellaneous contraception:

Some other contraception methods that are evaluated to check the effect on vaginal ecology are Nonoxynol-9, Progesterone vaginal rings and latex diaphragm.³⁰ Use of Nonoxynol 9 vaginal sponge had a dose dependent effect on increasing the colonization of anaerobic Gram negative rods, but the use of progesterone ring improved the Nugent score.³¹ The use of diaphragm did not demonstrate increased disruption of vaginal ecosystem.³²

3.6. Methods to assess vaginal health:

Various tests have evolved over past decades to assess the vaginal health. Vaginal pH is measured using vaginal pH strips and gloves, have high sensitivity in the range 72-79 %, but low specificity of 60-53% respectively.³³ Cervicovaginal lavage for cytokine analysis and vaginal epithelial exfoliation measurement are also used to assess the vaginal health.^{8,34} These specimen can be used to measure inflammatory markers like cytokines , free glycogen levels and exfoliated epithelial cells levels of which are associated with growth of different *Lactobacillus* species.³⁵ Further culturing techniques have allowed more specific strains to be identified, but vaginal microbiome analysis has gone step ahead to allow taxonomic and metabolomics analysis of the bacterial communities with respect to various vaginal infections. Two advanced microbial and metabolome techniques of next generation sequencing (NGS) and proton-based nuclear magnetic resonance spectroscopy are being used to identify the microbial picture and identify the functional correlation to various vaginal morbidities by analysing the metabolites.³⁶

4. Discussion:

It seems worthwhile to assess the literature related to vaginal milieu in women using various contraceptives to understand the short- and long-term effects of these contraceptives with respect to evolving literature of their effect on vaginal health.

The use of IUCD does seem to negatively affect the vaginal health during the initial period of use, probably because of the associated menstrual disturbances. Madden et al explained this association in 2012 possibly due to irregular vaginal bleeding which is commonly found in IUCD users. This blood increases the acidic pH of vagina as well as causes the agglutination of lactobacillus to red blood cells which may result in a decreased vaginal *Lactobacillus spp.* concentration in women with frequent or persistent uterine bleeding.¹³ The association between LNG IUCD and initial dysbiosis can be explained by the fact that use of LNG IUCD is associated with irregular vaginal bleeding initially and later there is cessation of blood flow after prolonged use, hence the microbiome which destabilizes after initial use and later balances itself. Donders et al study in the 2018 stated that, symptomatic or asymptomatic *Candida* colonization runs parallel to the growth of *Lactobacillus* because of preferential colonization of *Candida* with *Lactobacilli*.¹¹ Long-term use of LNG IUCD stabilizes the microbiome because of improvement in menstrual cycle. However more prospective and functional studies are required with use of LNG IUCD.

Two mechanisms are identified as how oestrogen and progesterone present in oral pills contribute to vaginal health. Hormonal stimulation leads to predominance of epithelial and intermediate cells and lysis of the latter leads to release of glycogen, which promotes the growth of *Lactobacillus spp.* like *L.crispatus* and *L.Gasseri*. These species converts glycogen into lactic acid and H₂O₂, which helps in improvising vaginal health by acting as bactericides. Activity of proton pump in the vaginal and cervical epithelial cells is enhanced in the presence of oestrogen hormone thereby decreasing the vaginal pH.^{7,37} Norgestrel, levonorgestrel and desogestrel are commonly used as a second and third generation

progesterone in oral contraceptive formulation. As highlighted by Achilles et al, the effect of progesterone on vaginal health will depend on their affinity to attach to the glucocorticoid receptors, mineralocorticoid receptor and androgen receptor, which are present in various cell. Activation of these leads to immunosuppression and mediates the non-contraceptive biological effects. The progesterone used in current OC formulation seem to have less effect on the glucocorticoid and mineralocorticoids receptor which in turn lowers the chances immune and genital infection susceptibility.^{7,18} Medroxyprogesterone acetate and gestodene are the only progesterone that have high affinity for this receptor. The rest have low affinity thereby less potential to effect the vaginal health.

DMPA is a progesterone with significant immunosuppressive effects as it strongly binds to the glucocorticoid receptors. Use of DMPA was thought to have a potential association between reproductive tract infection especially HIV transmission because of the hypoestrogenic state caused by prolonged use of DMPA leading to down regulates various genes involved in the maintenance of mucosal integrity.^{27,38} Though use of DMPA does not increase the risk of HIV infection as shown by ECHO trial , there is still evidence of increase in the colonization of anaerobic bacteria especially Prevotella OTUs and *A. vaginae* which further increase the potential for acquiring bacterial vaginosis.²⁵ This effect can also still be explained due to the prolonged hypoestrogenic state which decreases the glycogen in cells hence decrease substrate for Lactobacillus along with associated disturbed menstrual pattern promotes growth of anaerobic species in DMPA users. Romas et al in a recent study has suggested that DMPA causes increased cytokine profile, epithelial thinning and immunosuppressive response .³⁹

Though it is well known that use of condom is protective against sexually transmitted infections, less literature is available on the specific vaginal changes and microbiome associated with condom use. However, few studies states condom use along with dominance

of *Lactobacillus crispatus* is protective against sexually transmitted infections and HIV by enhancing the entrapment of these virus in the cervicovaginal mucosa.⁴⁰ This species of *Lactobacillus crispatus* has been shown to be protective against Chlamydia trachomatis, Gardenella vaginalis and Neisseria gonorrhoea infections too. However, the effect of other non-hormonal method on the vaginal health remains inconclusive owing to scanty literature available in the context. The peculiar microbiome associated with these contraceptive methods are not well explored and far less studies are available.

Evaluation of methods to assess vaginal health show that Vaginal pH is a relatively simple tool, but has disadvantages of false reading due to presence of mucus and semen inside the vagina.³³ Amsel's criteria described by Amsel in 1983 is not a gold standard method to assess the vaginal health owing to the component of whiff test which is very subjective but this test is favoured by clinicians as it eliminates the need of cumbersome laboratory equipment. The Amsel's criteria however does require some skill in microscopy to identify the clue cells and both conventional and modified Amsel's criteria hold similar diagnostic accuracy.^{41,42,43} Nugent score still remains the benchmark test to assess the vaginal health. Additional methods as illustrated by Sharma et al in 2018 who measured the cervico-vaginal cytokine levels highlighted the importance of cellular and cytokine milieu of the female genital tract mucosa which in turn determines the susceptibility for sexually tract infections. Non culture-based modern technologies like 16S rRNA gene sequencing greatly facilitate comprehensive surveys of the composition of vaginal microbial communities in comparison with the conventional methods. These molecular methods hold better speed, accuracy as well as ability to identify plethora of species which may not grow on culture media. Use of these advanced technologies has helped in taxonomic and metabolomics analysis of the vaginal ecosystem thereby helping to characterize the peculiar microbiome and metabolite associated with particular vaginal infection. This in turn may be useful in future to improve the

therapeutic interventions. Exploratory studies to evaluate the therapeutic options of vaginal microbiome transplantation in targeted subpopulations in underway. But the cost factor and elaborate infrastructure attached to it makes it of limited benefit in our day-to-day clinical work.

5. Conclusion:

The use of various available contraceptives is absolutely necessary but it does effect the vaginal health and further reproductive health of a women. There is need to periodically assess the vaginal milieu using various tests, which are appropriate as per available expertise, infrastructure and cost. Any dysbiosis should be immediately treated to prevent reproductive morbidities.

References:

1. World Family Planning Highlights 2020 Available at https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/un_desa_pd_hi_worldfamilyplanning2020_highlights.pdf Accessed on 25/2/21
2. Farage MA, Miller KW, Sobel JD. Dynamics of the Vaginal Ecosystem—Hormonal Influences. *Infectious Diseases: Research and Treatment*. January 2010. doi:[10.4137/IDRT.S3903](https://doi.org/10.4137/IDRT.S3903) Available from Dynamics of the Vaginal Ecosystem—Hormonal Influences (sagepub.com). Accessed on 25/2/21
3. Brown RG, Marchesi JR, Lee YS, Smith A, Lehne B, Kindinger LM et al. Vaginal dysbiosis increases risk of preterm fetal membrane rupture, neonatal sepsis and is exacerbated by erythromycin. *BMC Med*. 2018 Jan 24;16(1):9.
4. Van de Wijgert JHHM. The vaginal microbiome and sexually transmitted infections are interlinked: Consequences for treatment and prevention. *PLoS Med*. 2017 Dec 27;14(12):e1002478. doi: 10.1371/journal.pmed.1002478. PMID: 29281632; PMCID: PMC5744905.
5. Lewis FMT, Bernstein KT, Aral SO. Vaginal Microbiome and Its Relationship to Behavior, Sexual Health, and Sexually Transmitted Diseases. *Obstet Gynecol*. 2017 Apr;129(4):643-654.
6. Giraldo PC, Souza TC, Henrique GL, Monteiro I, Amaral R, Machado RB et al. Reactional changes in short-term levonorgestrel-releasing intrauterine system (Ing-ius) use. *Rev Assoc Med Bras*. 2019 ;65(6):857-863.
7. Achilles SL, Austin MN, Meyn LA, Mhlanga F, Chirenje ZM, Hillier SL. Impact of contraceptive initiation on vaginal microbiota. *Am J Obstet Gynecol* [Internet]. 2018;218(6):622.e1-622.e10. Available from: <https://doi.org/10.1016/j.ajog.2018.02.017>
8. Sharma P, Shahabi K, Spitzer R, Farrugia M, Kaul R, Yudin M. Cervico-vaginal

- inflammatory cytokine alterations after intrauterine contraceptive device insertion: A pilot study. *PLoS One*. 2018;13(12):6–12.
9. Brooks JP, Edwards DJ, Blithe DL, Fettweis JM, Serrano MG, Sheth NU et al. Effects of combined oral contraceptives, depot medroxyprogesterone acetate and the levonorgestrel-releasing intrauterine system on the vaginal microbiome. *Contraception*. 2017 Apr 1;95(4):405-13.
 10. Bassis CM, Allsworth JE, Wahl HN, Sack DE, Young VB, Bell JD. Effects of intrauterine contraception on the vaginal microbiota. *Contraception*. 2017 Sep 1;96(3):189-95
 11. Donders GG, Bellen G, Ruban K, Van Bulck B. Short-and long-term influence of the levonorgestrel-releasing intrauterine system (Mirena®) on vaginal microbiota and *Candida*. *Journal of medical microbiology*. 2018 ;67(3):308-13.
 12. Jacobson JC, Turok DK, Dermish AI, Nygaard IE, Settles ML. Vaginal microbiome changes with levonorgestrel intrauterine system placement. *Contraception*. 2014; Aug 1;90(2):130-5.
 13. Madden T, Grentzer JM, Secura GM, Allsworth JE, Peipert JF. Risk of bacterial vaginosis in users of the intrauterine device: a longitudinal study. *Sexually transmitted diseases*. 2012 Mar;39(3):217.
 14. Teeraganok T, Manonai J, Chongtrakool P. Vaginal health in copper intrauterine device users and non-users. *Thai Journal of Obstetrics and Gynaecology*. 2012:48-53.
 15. Neale R, Knight I, Keane F. Do users of the intrauterine system (Mirena) have different genital symptoms and vaginal flora than users of the intrauterine contraceptive device? *Int J STD AIDS*. 2009;20(6):423–4
 16. Lessard T, Simões JA, Discacciati MG, Hidalgo M, Bahamondes L. Cytological evaluation and investigation of the vaginal flora of long-term users of the levonorgestrel-

- releasing intrauterine system (LNG-IUS). *Contraception*. 2008 Jan 1;77(1):30-3.
17. Hashway SA, Bergin IL, Bassis CM, Uchihashi M, Schmidt KC, Young VB et al. Impact of a hormone-releasing intrauterine system on the vaginal microbiome: a prospective baboon model. *J Med Primatol*. 2014 Apr;43(2):89-99. doi: 10.1111/jmp.12090. Epub 2013 Nov 23. PMID: 24266633; PMCID: PMC3954920.
18. Fosch SE, Fico seco CA, Marchesi A, Cocucci S, Nader-Macias MEF, Perazzi BE. Contraception: Influence on Vaginal Microbiota and Identification of Vaginal Lactobacilli Using MALDI-TOF MS and 16S rDNA Sequencing. *Open Microbiol J*. 2018;12(1):218–29.
19. Brotman RM, P Gajer P, Robinson CK, Ma B, Humphrys M, Tuddenham S et al
Hormonal contraception is associated with stability and lactobacillus-dominance of the vaginal microbiota in a two-year observational study. *Sexually Transmitted Infections* 2015;91:A53.
20. Rifkin SB, Smith MR, Brotman RM, Gindi RM, Erbeling EJ. Hormonal contraception and risk of bacterial vaginosis diagnosis in an observational study of women attending STD clinics in Baltimore, MD. *Contraception*. 2009;80:63-7.
21. Vodstrcil LA, Plummer ME, Fairley CK, Tachedjian G, Law MG, Hocking JS et al. Combined oral contraceptive pill-exposure alone does not reduce the risk of bacterial vaginosis recurrence in a pilot randomised controlled trial. *Sci Rep*. 2019 ;9:3555.
22. Ralph LJ, McCoy SI, Shiu K, Padian NS. Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. *The Lancet infectious diseases*. 2015;15:181-9.
23. Yang L, Hao Y, Hu J, et al. Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women. *Emerging microbes & infections*. 2019;8:197-210.

24. Butler, Katherine MS, Ritter, DVM JM; Ellis, Shanon et al A Depot Medroxyprogesterone Acetate Dose That Models Human Use and Its Effect on Vaginal SHIV Acquisition Risk, JAIDS Journal of Acquired Immune Deficiency Syndromes: 2016,72(4).363-371.
25. Ahmed K, Baeten JM, Beksinska M, Bekker LG ,Bukusi EA, Donnell D et al. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. The Lancet. 2019 ;394:303-13.
26. Whitney BM, Guthrie BL, Srinivasan S, Tapia K, Muriuki EM, Chohan BH, et al. (2020) Changes in key vaginal bacteria among postpartum African women initiating intramuscular depot-medroxyprogesterone acetate. PLoS ONE 15(3): e0229586.
27. Zalenskaya IA, Chandra N, Yousefieh N, Fang X,Adedipe OE,Jackson SS et al. Use of contraceptive depot medroxyprogesterone acetate is associated with impaired cervicovaginal mucosal integrity. The Journal of clinical investigation.;128:4622-38.
28. Mitchell CM, McLemore L, Westerberg K, Astronomo R, Smythe K, Gardella C et al Long-term effect of depot medroxyprogesterone acetate on vaginal microbiota, epithelial thickness and HIV target cells. J Infect Dis. 2014;210(4):651-5.
29. Ma L, Lv Z, Su J, Wang J, Yan D, Wei J et al. Consistent condom use increases the colonization of Lactobacillus crispatus in the vagina. PLoS One. 2013 ;8(7):e70716. doi: 10.1371/journal.pone.0070716. PMID: 238
30. Kestelyn E, Agaba S, Van Nuil JI,et al. A randomised trial of a contraceptive vaginal ring in women at risk of HIV infection in Rwanda: Safety of intermittent and continuous use. PloS one. 2018;13(6).
31. Schreiber CA, Meyn LA, Creinin MD, Barnhart KT, Hillier SL. Effects of long-term use of nonoxynol-9 on vaginal flora. Obstetrics and gynecology. 2006 ;107(1):136-143

32. Cohen CR, Cheng SC, Shiboski S, Chipato T, Matu M, Mwangi J et al. Diaphragm used with replens gel and risk of bacterial vaginosis: results from a randomized controlled trial. *Infect Dis Obstet Gynecol.* 2012; 2012:921519. doi: 10.1155/2012/921519
33. Hemalatha R, Ramalaxmi BA, Swetha E, Balakrishna N, Mastromarino P. Evaluation of vaginal pH for detection of bacterial vaginosis. *The Indian journal of medical research.* 2013 Sep;138(3):354-9.
34. Amegashie CP, Gilbert NM, Peipert JF, Allsworth JE, Lewis WG, Lewis AL. Relationship between nugent score and vaginal epithelial exfoliation *PLoS One.* 2017;May 31;12(5)
35. Mirmonsef P, Hotton AL, Gilbert D, Burgad D, Landay A, Weber KM et al. Free glycogen in vaginal fluids is associated with *Lactobacillus* colonization and low vaginal pH. *PloS one.* 2014;9(7).
36. Ceccarani C, Foschi C, Parolin C, Antuono AD, Gaspari V, Consolandi C et al . Diversity of vaginal microbiome and metabolome during genital infections. *Scientific reports.* 2019 ;9:1-2.
37. Achilles SL, Hillier SL. The complexity of contraceptives: understanding their impact on genital immune cells and vaginal microbiota. *AIDS.* 2013;27 Suppl 1(0 1):S5-S15. doi:10.1097/QAD.0000000000000058
38. Hickey M, Marino JL, Tachedjian G. Critical Review: Mechanisms of HIV Transmission in Depo-Provera Users The Likely Role of Hypoestrogenism. *JAIDS Journal of Acquired Immune Deficiency Syndromes.* 2016 ;71(1):1-7.
39. Noël-Romas L, Perner M, Molatlhegi R, Farr Zuend C, Mabhula A, Hoger S et al. Vaginal microbiome-hormonal contraceptive interactions associate with the mucosal proteome and HIV acquisition. *PLoS Pathog* 2020 ;16(12): e1009097
40. Nunn KL, Wang YY, Harit D, Humphrys MS, Ma B, Cone R et al. Enhanced trapping of

HIV-1 by human cervicovaginal mucus is associated with *Lactobacillus crispatus*-dominant microbiota. *MBio*. 2015 30;6(5):e01084-15.

41. Mohammadzadeh F, Dolatian M, Jorjani M, AlaviMajd H. Diagnostic value of Amsel's clinical criteria for diagnosis of bacterial vaginosis. *Glob J Health Sci*. 2014;7(3):8–14. Published 2014 Oct 29.
42. Colonna C, Steelman M. Amsel Criteria. StatPearls Publishing. Available at <https://www.ncbi.nlm.nih.gov/books/NBK542319/> (Accessed on 1July 2019)
43. Mittal V, Jain A, Pradeep Y. Development of modified diagnostic criteria for bacterial vaginosis at peripheral health centres in developing countries. *The Journal of Infection in Developing Countries*. 2012;6(05):373-7.

Table I: Studies evaluating effect of Intrauterine contraceptive devices on vaginal milieu

Sr No	Author Year	Study Setting	Sample Size	Contraceptive Evaluated	Test used	Result
1.	Giraldo et al 2019 ⁶	Brasil	60	LNG IUCD [*]	pH, Pap smear, Gram Stain	No changes in vaginal pH, vaginal candidiasis, BV [□] , vaginal microbiota
2	Achilles et al 2018 ⁷	Zimbabwe	93	Copper T	PCR	Mean increase in Nugent score was 1.2
3	Sharma et al 2018 ⁸	Toronto	17	Copper T LNG IUCD [*]	Cytokine	Increase in inflammatory cytokines
4	Brooks et al 2017 ⁹	USA	682	LNG IUCD [*]	16S rRNA sequencing	<i>Prevotella</i> , <i>Sneathiaammii</i> , <i>Dialister</i> , and <i>Megasaera</i> species were significantly more abundant in LNG-IUS users
5	Bassis et al 2017 ¹⁰	USA	76	Copper T LNG IUCD [*]	16S rRNA sequencing	No evidence of altered vaginal microbiota composition.
6	Donders et al 2017 ¹¹	Belgian	252	LNG IUCD [*]	Gram stain, Culture	Initial three months increase BV, later stabilizes. More vaginal colonization with <i>Candida</i>
7.	Jacobson et al 2014 ¹²	-	11	LNG IUCD [*]	16S rRNA sequencing	No change in vaginal microbiome
8	Madden et al 2012 ¹³	-	153	Copper T	Gram stain	Intermediate flora, and irregular vaginal bleeding were significantly associated with BV [□]
9	Teeraganok	Thailand	92	Copper T	Amsel's	The prevalence of BV [□] was higher

	et al 2012 ¹⁴			Non users	criteria	among copper IUD ^{††} group
10	Neale et al 2009 ¹⁵	Truro	172	Copper T LNG IUCD [*]	Symptoms	More likely to have developed an abnormal vaginal discharge 4–6 weeks after insertion
11	Lessard et al 2007 ¹⁶	Brazil	187	LNG IUCD [*]	Cytology	Increased frequency of candida but no cytological changes after seven years

^{*}LNG IUCD Levonorgestrel Intra-uterine Contraceptive Device † BV- Bacterial vaginosis, †† IUD-Intrauterine device

Table II: Studies evaluating effect of Combined oral contraceptive pills on vaginal milieu

Sr No	Author Year	Study Setting	Sample Size	Contraceptive Evaluated	Test used	Result
1	Fosch et al 2017 ¹⁸	Argentina	84	COCP*	MALDI-TOF [†] MS, 16S rDNA	Stability in the vaginal ecosystem, though yeast colonization increases after sustained use
2	Brooks et al 2017 ⁹	USA	4306	COCP*	16S rRNA	Increase in residence of healthy vaginal flora and number of BV [‡] -associated bacteria was also reduced
3	Brotman et al 2016 ¹⁹	USA	108	COCP*	16S rRNA	Stable bacterial communities were found over the 2 year follow up
4	Rifkin et al 2009 ²⁰	Baltimore	330	COCP*	Amsel's criteria	Decreased risk of BV [‡] in an STD clinic cohort
5	Vodstrcil et al 2019 ²¹	Australia	95	COCP*	Amsel's criteria	COCP* exposure with antibiotics to the BV [‡] associated patients did not alter the BV [‡] recurrence

*COCP-combined oral contraceptive pills, †MALDI TOF-Matrix-Assisted Laser Desorption/Ionization-Time of Flight and MS- mass spectrometry, ‡ BV- Bacterial vaginosis

Table III: Studies evaluating effect of Depot medroxyprogesterone acetate(DMPA) on vaginal milieu

Sr. No.	Author Year	Study setting	Sample Size	Contraceptive Evaluated	Test	Result
1.	Whitney et al 2020 ²⁶	Kenya	54	DMPA	qPCR	Differential impacts on the vaginal concentrations
				Non HC*	Nugent score	<i>Sneathia</i> species, <i>Mycoplasma hominis</i> and <i>Parvimonas</i> species
2.	Yang et al 2019 ²³	USA	25	DMPA	16S rRNA Sequencing	The microbiome in Black women became more diversified and contained more VNAB [†] than Hispanic White women
3.	Zalenskaya et al 2018 ²⁷	USA	31	DMPA	Whole genome profiling	Altered expression of genes involved in the maintenance of epithelial integrity and differentiation
4.	Achillis et al 2018 ⁷	Zimbabwe	41	DMPA	PCR	Decreased concentration of <i>L.iners</i>
5.	Brooks et al 2017 ⁹	USA	94	DMPA	16S rRNA	Taxa associated with vaginal dysbiosis including <i>Dialistermicroaerophilus</i> , <i>Prevotella bivia</i> , <i>Prevotellaamii</i> and <i>Anaerococcus christensenii</i> more abundant
6.	Mitchell et al 2014 ²⁸	Germany	58	DMPA	Immuno-histochemical staining	Decrease CD3+ T lymphocytes and vaginal H ₂ O ₂ -producing lactobacilli

*Non HC – Non-Hormonal Contraceptive †VNAB- vaginosis-associated bacteria

Table IV: Studies evaluating the effect of condom on vaginal milieu

Sr. No.	Author Year	Study setting	Sample Size	Contraceptive Evaluated	Test used	Result
1	Fosch et al 2017 ⁹	Argentina	8	Condom	Culture,16S rRNA sequencing	Increase in the vaginal inflammatory reaction due to latex
2	Liyan Ma et al 2013 ²⁹	Canada	164	Condom	polymerase chain reaction(PCR), Nugent score & quantitative culture	<i>Lactobacilli crispatus</i> had higher colonization which was protective for BV and HIV